...
首页> 外文期刊>Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer >Soluble transferrin receptor and depth of bone marrow suppression following high dose chemotherapy.
【24h】

Soluble transferrin receptor and depth of bone marrow suppression following high dose chemotherapy.

机译:大剂量化疗后可溶性运铁蛋白受体和骨髓抑制深度。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Soluble transferrin receptor (sTfR) reflects erythropoietic activity in the bone marrow. We have sought to identify whether serial measurement of sTfR may predict depth or duration of myelosuppression in patients receiving high dose chemotherapy. MATERIALS AND METHODS: We prospectively measured serial sTfR in nine consecutive patients with haematologic malignancy admitted for various high dose regimens. The sTfR nadir was associated with white cell nadir, and sTfR nadir and day 5 sTfR were inversely associated with the number of red cell transfusions required. CONCLUSION: Our data suggest that sTfR may be helpful in predicting the degree of bone marrow suppression in patients receiving intensive chemotherapy.
机译:背景:可溶性转铁蛋白受体(sTfR)反映了骨髓中的促红细胞生成活性。我们试图确定连续测量sTfR是否可以预测接受大剂量化疗的患者骨髓抑制的深度或持续时间。材料和方法:我们前瞻性地测量了连续9例接受各种高剂量方案的血液系统恶性肿瘤患者的连续sTfR。 sTfR最低点与白细胞最低点相关,而sTfR最低点和第5天sTfR与所需的红细胞输注次数成反比。结论:我们的数据表明,sTfR可能有助于预测接受强化化疗的患者的骨髓抑制程度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号